Jiang Zhong PharmaceuticalLtd Valuation

Q: What is the Fair Price of 600750 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

600750 (CN¥20.31) is trading below our estimate of [[fair value]] (CN¥24)

Is 600750 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600750 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600750 (CN¥20.31) is trading below our estimate of fair value (CN¥24)

Significantly Below Fair Value: 600750 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600750?

Key metric: As 600750 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 600750. This is calculated by dividing 600750's market cap by their current earnings.
What is 600750's PE Ratio?
PE Ratio	16.9x
Earnings	CN¥750.31m
Market Cap	CN¥12.65b

600750 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3x
Enterprise Value/EBITDA	12x
PEG Ratio	1.3x

Price to Earnings Ratio vs Peers

How does 600750's PE Ratio compare to its peers?

The above table shows the PE ratio for 600750 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	31.1x
600285 Henan Lingrui Pharmaceutical	17.3x	16.1%	CN¥11.7b
688166 BrightGene Bio-Medical Technology	68.1x	34.8%	CN¥12.8b
603456 Zhejiang Jiuzhou Pharmaceutical	19.2x	20.2%	CN¥13.4b
002287 Tibet Cheezheng Tibetan Medicine	19.8x	n/a	CN¥11.7b
600750 Jiang Zhong PharmaceuticalLtd	16.9x	13.1%	CN¥12.6b

Price-To-Earnings vs Peers: 600750 is good value based on its Price-To-Earnings Ratio (16.9x) compared to the peer average (31.1x).

Price to Earnings Ratio vs Industry

How does 600750's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 600750 is good value based on its Price-To-Earnings Ratio (16.9x) compared to the CN Pharmaceuticals industry average (29.6x).

Price to Earnings Ratio vs Fair Ratio

What is 600750's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600750 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	16.9x
Fair PE Ratio	23.9x

Price-To-Earnings vs Fair Ratio: 600750 is good value based on its Price-To-Earnings Ratio (16.9x) compared to the estimated Fair Price-To-Earnings Ratio (23.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 600750 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CN¥20.31	CN¥28.00 +37.9%	8.7%	CN¥31.00	CN¥25.00	n/a	3
Nov ’25	CN¥20.89	CN¥28.31 +35.5%	7.7%	CN¥31.00	CN¥25.00	n/a	4
Oct ’25	CN¥23.60	CN¥28.41 +20.4%	8.9%	CN¥31.00	CN¥25.00	n/a	3
Sep ’25	CN¥21.05	CN¥31.08 +47.6%	4.9%	CN¥33.00	CN¥29.24	n/a	3
Aug ’25	CN¥22.44	CN¥31.08 +38.5%	4.9%	CN¥33.00	CN¥29.24	n/a	3
Jul ’25	CN¥23.76	CN¥31.08 +30.8%	4.9%	CN¥33.00	CN¥29.24	n/a	3
Jun ’25	CN¥26.07	CN¥31.12 +19.4%	6.0%	CN¥33.00	CN¥29.24	n/a	2
May ’25	CN¥26.66	CN¥31.12 +16.7%	6.0%	CN¥33.00	CN¥29.24	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

-3.0%

13.2%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

-4.2%

-23.6%